US melatonin demand and supplier activity maintained a steady, orderly tone into early February, supported by ready procurement from formulators and routine offers from exporters. Weekly data show a modest week-on-week gain, sustaining a multi-week bullish trajectory. Early January activity was range-bound but constructive, with late-month cautious buying underpinning momentum into February. Market dynamics reflected cautious yet sustained demand for finished formulations and steady outlet offers, contributing to a calm trading environment and gradual price appreciation, without sharp swings. Production remained stable with normal operating rates, and upstream inputs were broadly unchanged, limiting cost pressure on manufacturers. No notable outages or disruptions were reported, enabling a healthy supply-demand balance. The overall tone suggests continued measured strength, provided procurement patterns remain steady and production stays on track. Seasonal drivers are not prominent; any material shift would likely stem from shifts in orders or unforeseen supply disruptions. Market participants expect price stability as fundamentals remain balanced and visibility improves.
The market value of Melatonin in the US was increased as market moved from January 2026 into early February 2026, with a measured upward tilt driven by steady demand and balanced supply conditions. The early January activity was range-bound but supportive, while late-month cautious procurement helped sustain momentum into the first week of February 2026. According to ChemAnalyst data, the market extended a multi-week bullish bias and the month-on-month picture for January showed a modest rise overall. The tone remained orderly rather than volatile with Melatonin market participants citing routine procurement patterns and consistent production as the backdrop for the latest gains.
The Melatonin formulators have played a central role in underpinning the market with procurement for finished formulations described as cautious but supportive, a factor that helped prevent sharp swings across the Melatonin value chain. In contrast, the Melatonin exporters and traders have maintained steady routine offers, which contributed to a calm trading environment and a steady upward trend. General buyers and mid-month activity reflected balanced supply–demand conditions, and ChemAnalyst data notes an ongoing bullish run spanning the recent 12-week period. While no single end-use segment exerted outsized pressure, the combined effect of formulators measured buying and exporters’ steady offers kept the market on a gradual ascent.
The production-side dynamics was broadly stable throughout the month with consistent Melatonin output and normal operating rates cited as key stabilizers. The upstream input costs were reported as essentially unchanged which resulted in no material shift to production costs or margins and limited the upward pressure from the supply side. There were no notable plant outages or prolonged shutdowns impacting the Melatonin availability. The Melatonin manufacturers were comfortable with current operating schedules. The energy and feedstock influences were not a primary driver this period with the net effect being a healthy supply–demand balance that allowed for orderly appreciation in Melatonin prices.
ChemAnalyst after assessed weekly data, the Melatonin prices rose by 1.00% week-on-week for the week ending Feb 01, 2026 and continued the recent bullish sequence. The Melatonin prices trended higher through late January before this early-February uptick and was supported by the steady buying interest and lacklustre volatility. Rather than large swings, the Melatonin market showed incremental advances that extended the multi-week upward trend; small weekly gains accumulated into a modest month-on-month increase. The market activity was characterized by routine transactions and limited speculative pressure which kept week-to-week moves measured and predictable.
ChemAnalyst anticipates continued measured strength, contingent on sustained procuring behaviour from Melatonin formulators and steady export flows. Our analysts view the market to remain supported as long as production stays consistent and upstream costs remain stable. The seasonal factors are not prominent in existing signals, so any material change would likely stem from shifts in procurement patterns or unexpected supply disruptions.
